establish the cause of death. Finally, Inman expresses his concern at the way in which the news media have prejudged the issue of safety of drugs beforeadequate information had been obtained in sufficient numbers of patients for a truly balanced view to be placed before the medical community. 'Confidence in drug treatment is being seriously eroded by the activities of the media' says Inman, and it is an opinion that few doctors would dispute.
This first newsletter reports an encouraging start of an enterprise which needs wholehearted support from the government, pharmaceutical industry, prescribing doctor and clinical academic profession. An independent, impartial facility for post-marketing surveillance now exists in the United Kingdom, and the CSM should consider restricting product licences on more new drugs and formulations until the results of PEM studies demonstrate acceptable safety. PEM is relatively cheap compared with most other methods of drug surveillance, and Inman anticipates that it should identify adverse drug reactions which have an incidence of one in 3000 or greater. Important reactions with a lower incidence will probably still depend on Yellow Card reporting to identify them (Inman 1981a) .
What about the assessment of drug efficacy?
There is no alternative to long-term controlled therapeutic trials to determine the true and comparative efficacy of a drug and its place in patient management, and PEM has not been designed to make a major contribution to this. Nevertheless, clues to comparative therapeutic efficacy may appear and prompt further controlled studies. Inman & Rawson (1983) have recently drawn attention to a less-than-expected number of reports of death from myocardial infarction in patients receiving treatment with zomepirac during a PEM study, and have asked whether it exerts a protective effect against cardiovascular death. This question deserves prospective investigation, but, whatever the answer, it illustrates that PEM may well help to identify unexpected therapeutic benefit as well as unwanted effects of drugs.
Paul Prevention of cytomegalovirus infection' When Weller & Hanshaw (1962) discovered twenty years ago that the human cytomegalovirus (CMV) caused congenital infection, the extent of the problem could not be foreseen. Over the years Hanshaw et al. (1976) , the University of Alabama group under Alford and Stagno (Reynolds et al. 1974 , Stagno et al. 1977a .and Stern & Tucker (1973) in England developed data that demonstrated the public health importance of congenital CMV.
Most observers are now willing to attribute to CMV the title of most common infectious cause of brain damage, with a rate of about 0.1 to 0.3 of all infants born in the US or the UK. Meanwhile, since the early 1960s, the importance of CMV disease has become obvious in renal, bone marrow and cardiac transplant patients. Moreover, transmission of CMV by blood transfusion for surgery or for replenishment of falling haemoglobins in premature infants has been identified as a significant cause of morbidity and mortality. Finally, it is now appreciated that CMV is often transmitted sexually, and that this venereal infection can express itself in a variety of ways: as part of the AIDS syndrome in homosexual men, as cervical infection in women, as acquired neonatal infection in infants born to those women and as infection of the semen in both heterosexual and homosexual men.
In addition to exogenous transmission, studies of transplant CMV infections have also shown that endogenous virus can reactivate in the face of pre-existing immunity, when that immunity is tampered with. A similar process explains the observations that seropositive mothers become cervical excretors late in pregnancy and that fetal infection may take place in their infants.
It needs no sophistication to realize that an infection transmitted in so many different ways, with the capacity to cause disease both during primary infection and by reactivation, would pose novel and difficult problems for the development of prevention. Nevertheless, there are promising developments taking place in the categories of live vaccine, killed vaccine, passive antibody, and prophylactic antivirals. These developments were reviewed at two recent meetings, one held at Philadelphia in April 1983 , and the other held at the Royal Society of Medicine in May 1983. Harold Stern (1984) , who first attempted live CMV virus vaccination, presented follow-up data on his original vaccinees. We reviewed our now considerable experience on the use of Towne CMV vaccine in normal volunteers and renal transplant patients (Plotkin et al. 1984b ). In normals, vaccination produced an asymptomatic infection, without viral excretion, but with the regular development of humoral antibodies and cellular sensitization to CMV antigens similar to those that follow natural infection. By most immunologic assays there was no evidence of strain specificity, although neutralization tests showed incomplete cross-antigenicity.
In renal transplant patients, immune responses to live CMV vaccine were considerably weaker than in normal volunteers, because uraemia is immunosuppressive. Nevertheless, because of the high attack rate for CMV disease, it was considered ethical to start a trial of safety and efficacy in prospective renal transplant recipients. The first results of these controlled trials, conducted both at the University of Pennsylvania and the University of Minnesota, show that the Towne vaccinees, despite their relatively poor immune responses, were significantly protected from the severe CMV disease that occurred in placebo recipients.
Interestingly, while the patients frequently became infected with CMV regardless of their vaccine status, evidence was. adduced by genetic analysis of the strains that the infecting viruses were exogenous in origin, presumably coming in with the transplanted kidney, rather than being reactivated vaccine virus.
Meanwhile, since some workers prefer not to use a live herpesvirus vaccine because of fear of oncogenicity, promising research is going on to identify protective antigens for use in a subunit vaccine. At least two glycoproteins have been identified that have neutralizing specificities, and one has been used by John Zaia (1984) to immunize guinea-pigs. In addition; noninfectious but immunogenic particles have been described which do not contain viral DNA.
For organ transplant patients, however, other prophylaxis is possible. Groups from Minnesota (Condie 1984) and Los Angeles (Winston et al. 1984) have been able to reduce the incidence of primary CMV infection by repeated inoculations of CMV antibody-containing plasma, and immune globulin. Hirsch et al. (1984) , in Boston, have successfully used interferon to reduce the incidence of reactivation disease. An approach combining interferon, antibody, and newer antivirals that (unlike the previously available ones) are active against CMV might prevent the majority of CMV disease complicating organ transplantation.
For the protection of pregnant women, however, only active immunization is likely to work. The ideal vaccine would be given to girls at or before puberty, and would provide immunity for the duration of child-bearing. The problem here is choice: a live vaccine might provide durable immunity, but some are concerned about latency and reactivation of the vaccine virus genome; whereas a subunit vaccine would be safe but might not provide immunity over such a long period. In this regard, it is instructive that, in both guinea-pig and murine CMV models, killed vaccines were inferior to live in protection (Bia et al. 1984) .
To validate the efficacy of CMV vaccines in preventing fetal infection one would ideally require a trial encompassing thousands of women inoculated before pregnancy. Such a trial was never performed in the case of rubella vaccine and it may be that the only feasible strategy to tell us whether or not a vaccine will work involves trials in nonpregnant volunteers challenged with unattenuated CMV.
In any case, the future of CMV vaccines, though complex, is far from bleak.
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